Relative risks of TRM, relapse, and treatment failure after PBSC and BM transplantation
. | Previous report . | . | Current report . | . | ||
|---|---|---|---|---|---|---|
| Patient group . | No. BM/no. PBSC . | RR (95% CI); P . | No. BM/no. PBSC* . | RR (95% CI); P . | ||
| TRM† | ||||||
| AL, CR1 | 180/95 | 0.59 (0.33-1.07); .25 | 156/81 | 1.03 (0.62-1.71); .84 | ||
| AL, CR2 | 40/31 | 0.36 (0.13-0.99); .04 | 31/30 | 0.35 (0.13-0.97); .04 | ||
| CML, CP1‡ | 214/91 | 1.33 (0.82-2.15); .27 | 188/76 | 1.61 (1.05-2.46); .03 | ||
| CML, CP2/AP‡ | 28/27 | 0.28 (0.12-0.67); .004 | 23/21 | 0.43 (0.18-1.02); .06 | ||
| Relapse† | ||||||
| AL, CR1 | 180/95 | 0.57 (0.04-7.66); .67 | 156/81 | 0.91 (0.47-1.75); .77 | ||
| AL, CR2 | 40/31 | 0.24 (0.01-4.42); .34 | 31/30 | 1.04 (0.43-2.55); .93 | ||
| CML, CP‡ | 183/95 | 0.48 (0.01-56.97); .76 | 188/76 | 0.49 (0.11-2.21); .36 | ||
| CML, CP2/AP‡ | 28/27 | 1.02 (0.07-14.99); .99 | 23/21 | 0.37 (0.10-1.44); .15 | ||
| TF† | ||||||
| AL, CR1 | 180/95 | 0.76 (0.48-1.21); .25 | 156/81 | 1.01 (0.67-1.51); .97 | ||
| AL, CR2 | 40/31 | 0.40 (0.18-0.92); .03 | 31/30 | 0.60 (0.31-1.16); .13 | ||
| CML, CP‡ | 214/91 | 1.30 (0.82-2.08); .27 | 188/76 | 1.57 (1.05-2.35); .03 | ||
| CML, CP2/AP‡ | 28/27 | 0.29 (0.14-0.59); < .001 | 23/21 | 0.42 (0.20-0.86); .02 | ||
. | Previous report . | . | Current report . | . | ||
|---|---|---|---|---|---|---|
| Patient group . | No. BM/no. PBSC . | RR (95% CI); P . | No. BM/no. PBSC* . | RR (95% CI); P . | ||
| TRM† | ||||||
| AL, CR1 | 180/95 | 0.59 (0.33-1.07); .25 | 156/81 | 1.03 (0.62-1.71); .84 | ||
| AL, CR2 | 40/31 | 0.36 (0.13-0.99); .04 | 31/30 | 0.35 (0.13-0.97); .04 | ||
| CML, CP1‡ | 214/91 | 1.33 (0.82-2.15); .27 | 188/76 | 1.61 (1.05-2.46); .03 | ||
| CML, CP2/AP‡ | 28/27 | 0.28 (0.12-0.67); .004 | 23/21 | 0.43 (0.18-1.02); .06 | ||
| Relapse† | ||||||
| AL, CR1 | 180/95 | 0.57 (0.04-7.66); .67 | 156/81 | 0.91 (0.47-1.75); .77 | ||
| AL, CR2 | 40/31 | 0.24 (0.01-4.42); .34 | 31/30 | 1.04 (0.43-2.55); .93 | ||
| CML, CP‡ | 183/95 | 0.48 (0.01-56.97); .76 | 188/76 | 0.49 (0.11-2.21); .36 | ||
| CML, CP2/AP‡ | 28/27 | 1.02 (0.07-14.99); .99 | 23/21 | 0.37 (0.10-1.44); .15 | ||
| TF† | ||||||
| AL, CR1 | 180/95 | 0.76 (0.48-1.21); .25 | 156/81 | 1.01 (0.67-1.51); .97 | ||
| AL, CR2 | 40/31 | 0.40 (0.18-0.92); .03 | 31/30 | 0.60 (0.31-1.16); .13 | ||
| CML, CP‡ | 214/91 | 1.30 (0.82-2.08); .27 | 188/76 | 1.57 (1.05-2.35); .03 | ||
| CML, CP2/AP‡ | 28/27 | 0.29 (0.14-0.59); < .001 | 23/21 | 0.42 (0.20-0.86); .02 | ||
Relative risk of less than 1.0 indicates an advantage for PBSC transplantation (lower risk of adverse outcome) and a relative risk of greater than 1.0 indicates an advantage for BM transplantation (higher risk of adverse outcome).
TRM indicates transplant-related mortality; TF, treatment failure inverse of LFS; AL, acute leukemia; CR, clinical remission; CML, chronic myeloid leukemia; CP, chronic phase; AP, accelerated phase.
The current report is limited to transplantation centers that provided extended follow-up data on more than 90% of their patients; 100 of 706 patients from 20 centers were excluded. Therefore, the current study includes 606 patients (398 BM and 208 PBSC transplantations).
Model stratified on use of growth factor.
PBSC and BM recipients had similar European Group for Blood and Marrow Transplantation risk score at transplantation.